Monoamine Reuptake Inhibitors in Parkinson’s Disease
The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughou...
Saved in:
| Main Authors: | Philippe Huot, Susan H. Fox, Jonathan M. Brotchie |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2015/609428 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Selective serotonin reuptake inhibitors and spermatogenesis
by: M. N. Korshunov, et al.
Published: (2021-07-01) -
Dual Inhibitors of Acetylcholinesterase and Monoamine Oxidase-B for the Treatment of Alzheimer’s Disease
by: Ayesha Asim, et al.
Published: (2025-07-01) -
Selective serotonin reuptake inhibitors and pharmacological resetting of the mind
by: Ion G. Motofei, et al.
Published: (2024-04-01) -
Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
by: Natan Pereira Gosmann, et al.
Published: (2021-06-01) -
Effect of Selective Serotonin Reuptake Inhibitors on Coagulation: Fact or Fiction?
by: Antoine Mokhtarian, et al.
Published: (2025-03-01)